Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a BetZacks Investment Research · 2 days ago
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe AcneGlobeNewsWire · 3 days ago
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery BetSeeking Alpha · 4 days ago
Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head ComparisonDefense World · Oct 16, 2026
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)Zacks Investment Research · Oct 15, 2026
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceGlobeNewsWire · Oct 9, 2026Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.25 | -$0.26 | Miss |
| May 12, 2026 | -$0.39 | -$0.33 | Beat |
| Mar 11, 2026 | -$0.43 | -$0.29 | Beat |
| Nov 13, 2025 | -$0.41 | -$0.40 | Beat |
| Aug 13, 2025 | -$0.52 | -$0.32 | Beat |
| May 8, 2025 | -$0.79 | -$0.56 | Beat |